AOD-9604 in Maubert — Fat Loss Peptide Research Guide
AOD-9604 research guide for Maubert. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Maubert searching for AOD-9604, the foundational reality is that this compound is available only through an online research supply market. This concentration of supply in online vendors is a genuine benefit for researchers — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. A credible AOD-9604 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. This guide guides Maubert researchers through that evaluation process and explains what quality documentation for AOD-9604 should look like.
How AOD-9604 Works — Mechanisms & Research
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Maubert studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Where to Buy AOD-9604 — A Researcher's Guide
The most consistent path to quality AOD-9604 is community research first — peptide forums aggregate real purchasing experience that are more reliable than search results. When reviewing a AOD-9604 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are within acceptable research limits. For Maubert researchers evaluating unfamiliar vendors: a small initial order to verify quality before committing to research quantities is what experienced peptide researchers consistently do. Price is an poor proxy for AOD-9604 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so the lowest-priced options almost always involve trade-offs.
Order AOD-9604 — ships to Maubert
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and small-scale human observations. Temperature excursions — even short periods above −20°C — can compromise product integrity without any obvious sign; always use only material shipped with appropriate cold protection. Verify the endotoxin level in your AOD-9604 batch COA before any injectable research application — look for results reported in endotoxin units per mg or mL and confirm they fall within appropriate thresholds. PubMed and bioRxiv are the primary literature resources for AOD-9604 research; favour indexed journal publications over preprints over conference abstracts or single case observations.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
